tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Minerva Neurosciences Reports Improved 2024 Financials
PremiumCompany AnnouncementsMinerva Neurosciences Reports Improved 2024 Financials
5M ago
Hold Rating for Minerva Neurosciences Amidst Uncertainty Over Roluperidone and Financial Constraints
Premium
Ratings
Hold Rating for Minerva Neurosciences Amidst Uncertainty Over Roluperidone and Financial Constraints
6M ago
Minerva reports Q4 EPS (56c) vs. ($1.19) last year
Premium
The Fly
Minerva reports Q4 EPS (56c) vs. ($1.19) last year
6M ago
Minerva reports Q EPS ($1.09) vs ($1.12 ) last year
PremiumThe FlyMinerva reports Q EPS ($1.09) vs ($1.12 ) last year
1y ago
NERV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
NERV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1y ago
Minerva Neurosciences Announces Board and Audit Committee Changes
Premium
Company Announcements
Minerva Neurosciences Announces Board and Audit Committee Changes
1y ago
Minerva trading resumes
PremiumThe FlyMinerva trading resumes
1y ago
Minerva trading halted, volatility trading pause
Premium
The Fly
Minerva trading halted, volatility trading pause
1y ago
Minerva receives complete response letter from FDA for NDA for roluperidone
Premium
The Fly
Minerva receives complete response letter from FDA for NDA for roluperidone
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100